What is Neurogene?
Neurogene is a clinical-stage biotechnology company dedicated to the development of life-altering genetic medicines. The firm utilizes proprietary AAV vector-based gene therapy technology to deliver functional genes to patients suffering from rare neurological diseases. By fostering deep collaborations with academic researchers, patient advocacy groups, and caregivers, Neurogene bridges the gap between complex genetic science and patient-centric care. Their platform is uniquely designed to overcome the limitations of conventional gene therapy, allowing for the treatment of conditions that were previously considered unreachable by standard medical modalities.
How much funding has Neurogene raised?
Neurogene has raised a total of $383.5M across 3 funding rounds:
Series A
$68.5M
Series B
$115M
Share Placement
$200M
Series A (2019): $68.5M, investors not publicly disclosed
Series B (2020): $115M led by Casdin Capital , LLC, Janus Henderson Group plc, EcoR1 Capital LLC, Avidity Partners LLC, and BlackRock
Share Placement (2024): $200M, investors not publicly disclosed
Key Investors in Neurogene
BlackRock
BlackRock is a global investment management firm providing institutional clients with comprehensive risk management and advisory services across diverse asset classes.
Casdin Capital, LLC
A specialized investment firm focused on the life sciences and healthcare sectors, providing strategic backing to innovative biotechnology companies.
Janus Henderson Group plc
A global asset management group that provides a wide range of financial services and investment solutions to institutional and individual investors.
What's next for Neurogene?
With the recent $200M in capital, Neurogene is well-positioned to scale its research and development operations. The company's strategic roadmap likely involves advancing its lead programs through critical clinical trial phases and expanding its technological infrastructure to support a broader spectrum of neurological indications. As the firm transitions into this next phase of growth, the focus will remain on regulatory milestones and the potential commercialization of its gene therapy candidates. Investors and stakeholders are closely monitoring the company's ability to translate its innovative AAV platform into tangible patient outcomes, which will be the primary driver of long-term value creation in the competitive landscape of genetic medicine.
See full Neurogene company page
